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Abstract
Introduction. Group B streptococcus (GBS) is a leading cause of invasive neonatal infections. These have been divided into 
early- onset disease (EOD; <7 days) and late- onset disease (LOD; 7–89 days), with different GBS clonal complexes (CCs) associ-
ated with different disease presentations.
Hypothesis. Different GBS CCs are associated with timing of infection (EOD or LOD) and clinical presentation (sepsis, meningitis 
or pneumonia).
Aim. To study infant GBS infections in Iceland from 1975 to 2019. Are specific GBS CCs related to disease presentation? Is CC17 
overrepresented in infant GBS infections in Iceland?
Methodology. All culture- confirmed invasive GBS infections in infants (<90 days) in Iceland from 1975 to 2019 were included. 
Clinical information was gathered from medical records.
Results. A total of 127 invasive GBS infections in infants were diagnosed, but 105 infants were included in the study. Of these, 
56 had EOD and 49 had LOD. The incidence of GBS infections declined from 2000 onwards but increased again at the end of the 
study period. Furthermore, there was a significant increase in LOD over the study period (P=0.0001). The most common pre-
senting symptoms were respiratory difficulties and fever and the most common presentation was sepsis alone. Approximately 
one- third of the cases were caused by GBS CC17 of serotype III with surface protein RIB and pili PI-1+ PI- 2b or PI- 2b. CC17 was 
significantly associated with LOD (P<0.001).
Conclusion. CC17 is a major cause of GBS infection in infants in Iceland. This clone is associated with LOD, which has been 
increasing in incidence. Because intrapartum antibiotic prophylaxis only prevents EOD, it is important to continue the develop-
ment of a GBS vaccine in order to prevent LOD infections.
INTRODUCTION
Streptococcus agalactiae or group B streptococcus (GBS) 
is a leading cause of invasive neonatal infections [1]. The 
bacterium colonizes the gastrointestinal and genital tracts of 
humans [2, 3] and up to 44 % of women carry GBS in the 
vagina during pregnancy [4–8]. Most commonly, GBS infec-
tions of newborns occur because of an ascending infection in 
pregnancy or the newborn becomes colonized during passage 
through the birth canal [2]. Approximately half of infants born 
to women who are carriers of GBS will be colonized, but only 
1–2 % of those will develop an invasive GBS infection [2, 3].
Infections in infants have been divided into early- onset 
disease (EOD) occurring 1–6 days after birth and late- onset 
disease (LOD) occurring 7–89 days after birth [2, 9]. GBS 
disease in infants most commonly presents as sepsis, pneu-
monia or meningitis [1, 2, 9] and studies have shown that 
meningitis is significantly more common in LOD [9, 10]. 
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colonization, premature rupture of membranes (PROM), 
preterm delivery (<37 weeks’ gestation), prolonged rupture 
of membranes (≥24 h), chorioamnionitis and intrapartum 
fever ≥38 °C) [2, 3, 11]. More than 80 % of infants with EOD 
present with respiratory distress, i.e. tachypnea or grunting, 
with retractions and nasal flaring. Infections can also present 
as apnea, especially in the preterm infant [2]. Maternal colo-
nization of GBS is also a risk factor for LOD and many infants 
who get LOD are born preterm [12]. Other risk factors for 
LOD, such as nosocomial transmission and contaminated 
breast milk, have been postulated [12]. Clinical signs of LOD 
infections in infants are often nonspecific [2].
Discussion of preventive measures against GBS infections in 
infants started around 1990 [13]. Since then many countries 
have implemented preventive measures, giving intrapartum 
antibiotic prophylaxis based on risk factors or screening for 
GBS in pregnancy [1, 14]. Following these measures the inci-
dence of EOD but not LOD has declined [1], and some studies 
have suggested that the incidence of LOD may be increasing 
[15, 16]. The incidence of all GBS infections in infants from 
0 to 89 days of age is reported to be 0.49–0.53/1000 live births 
[17, 18].
An important virulence factor for GBS is the capsular poly-
saccharide (CPS), which has been used for serotyping and 
Table 1. Information on pregnancy, delivery, GBS risk factors and perinatal clinical factors of 105 infants with GBS infection in Iceland from 1975 to 
2019
  Early- onset disease (EOD) Late- onset disease (LOD) All cases P- value
No. (%) No. (%) No. (%)
No. of cases (%) 56 (53) 49 (47) 105 (100)
Infant
  Female 19 (34) 26 (53) 45 (43) 0.08
  Male 37 (66) 23 (47) 60 (57) 0.08
  APGAR 1 min 7 [5–8]* 8 [6–8]* 8 [6–8]* 0.45
  APGAR 5 min 9 [7–9]* 9 [8–10]* 9 [7–10]* 0.11
  Age at diagnosis (days) 1 [0–1]* 23 [15–53]* 2 [1–21]*
  Deaths 5 (9) 0 (0) 5 (5) 0.06
Pregnancy and delivery
  Birthweight (g) 3675 [2998–4083]* 3100 [2123–3837]* 3480 [2573–4030]* 0.008
  Gestational age (days) 280 [259–286]* 274 [245–283]* 276 [253–286]* 0.19
  Twins 2 (4) 7 (14) 9 (9) 0.08
  Preterm (<37 weeks) 14 (25) 17 (35) 31 (30) 0.31
  Emergency c- section 9 (16) 10 (20) 19 (18) 0.67
  Elective c- section 0 (0) 2 (4) 2 (2) 0.21
  Assisted delivery 7 (13) 7 (14) 14 (13) 0.78
  Intrapartum antibiotics 6 (11) 8 (16) 14 (13) 0.46
  Mother diagnosed
  with chorioamnionitis
5 (9) 1 (2) 6 (6) 0.22
Known risk factors
  Mother known GBS
  carrier
4 (7) 4 (8) 8 (8) 0.73
  Premature rupture of membranes 
(PROM)
29(52) 14 (29) 43 (41) 0.09
  Prolonged PROM
  >24 h before birth
13 (23) 4 (8) 17 (16) 0.09
Intrapartum fever ≥38 °C 10 (18) 3 (6) 13 (12) 0.19
*Median (interquartile range).
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understanding the epidemiology of GBS [19]. To date, 10 
different types of CPS have been described (Ia, Ib and II–IX) 
and the most common serotype in neonatal infections is type 
III [19]. GBS also has three different types of pili and a few 
types of surface proteins [alpha- like proteins such as C alpha 
(BCA), rib (RIB), epsilon (EPS) and alpha- like proteins 2–4 
(ALP2-4)] that have been identified [20]. In recent years, 
with more advanced molecular methods such as multilocus 
sequence typing (MLST), GBS has been categorized into 
several sequence types (STs) and clonal complexes (CCs) 
according to genetic relatedness [21].
The aim of this study was to describe GBS infections in infants 
in Iceland from 1975 to 2019 and determine if there is a rela-
tionship between the clinical presentation of GBS infections 
and microbiological factors of the bacteria, such as serotypes, 
CCs, surface proteins and pili, and also to determine if clonal 
complex 17 is overrepresented in infections in Icelandic 
infants, as has been shown in studies from other countries 
[22–24].
METHODS
All culture- confirmed invasive GBS infections (from blood 
or cerebrospinal fluid) in infants (<90 days) in Iceland in the 
years 1975–2019 were included. The data were accessible 
from the database of the Department of Clinical Microbi-
ology, Landspitali University Hospital. Clinical information 
was gathered from infant and maternal medical records 
using national identification numbers. Information on the 
following variables related to pregnancy and birth were 
collected: gestational age, complications during pregnancy, 
mode of delivery, maternal GBS status, premature rupture 
of membranes (PROM), maternal fever  ≥38 °C during 
delivery, intrapartum antibiotic prophylaxis and diagnosed 
chorioamnionitis. The following variables were gathered 
regarding the infant and clinical presentation of the infec-
tion: gender, birth weight, APGAR score, age at diagnosis, 
first clinical signs of infection, results from blood culture 
and culture from cerebrospinal fluid, antibiotic treatment, 
number of days in hospital, diagnosis of sepsis, meningitis 
and/or pneumonia and deaths.
All available isolates from all GBS infections during the 
study period were kept frozen at the department. Serotyping 
had been performed earlier at the Department of Clinical 
Microbiology, Landspitali University Hospital, Reykjavik, 
Iceland and at the Faculdade de Medicina, Universidade 
de Lisboa, Lisbon, Portugal by one of the authors (E. S.B.), 
as recently published [25, 26]. Capsular serotyping was 
performed by latex agglutination test [27]. MLST was 
used to categorize the bacteria into sequence types (STs) 
[28] and from that into clonal complexes (CCs) using the 
goeBURST algorithm [21]. A multiplex polymerase chain 
reaction (PCR) was used to test for the presence of pili and 
surface protein genes [29].
Statistical analysis and graphical representation were 
performed using the software Rstudio. The chi- squared 
test and Fisher’s exact test were used to compare two 
categorical variables, the two- sample t- test was used 
to compare two means of continuous variables and the 
Wilcoxon test was used to compare two medians of non- 
normally distributed continuous variables. Correction for 
multiple testing was done with the Bonferroni method 
where appropriate. Poisson regression was used for anal-
ysis of the incidence of GBS infections. Information on 
live births in Iceland was obtained from Statistics Iceland 
( www. statice. is). Results were considered significant if the 
P- value was <0.05.
The study was approved by The National Bioethics 
Committee (VSNb2015120015/03.03.) with later adapta-
tions and the medical director of Landspitali, University 
Hospital.
Fig. 1. Epidemiology of invasive GBS infections in infants (<90 days old) in Iceland from 1975 to 2019. (a) Incidence of invasive GBS 
infections in infants from 1975 to 2019 divided by 5- year periods. All GBS infections in infants (n=124) are included, regardless of the 
availability of the isolate; three GBS reinfections were excluded. In total, there were 68 cases of EOD and 56 cases of LOD during the 
study period. (b) Clonal complexes (CCs) of GBS isolates in infants in Iceland from 1975 to 2019 divided by 5- year periods. Isolates were 
of seven different CCs.
4
Baeringsdottir et al., Journal of Medical Microbiology 2021;70:001426
RESULTS
The number of invasive GBS infections in infants (<90 days) 
in Iceland from 1975 to 2019 was 127, and of these 3 infants 
were reinfected [year 1984 at days 1 (CC17, serotype III, 
surface protein gene RIB, pili PI-1 +PI- 2b) and 35 (isolate 
not available); year 1989 at days 24 (CC17, serotype III, 
surface protein gene RIB, pili PI-1 +PI- 2b) and 41 (isolate 
not available); year 2017 at days 11 and 40 (both isolates 
CC17, serotype III, surface protein gene RIB, pili PI- 2b)]. 
Of those infections, 107 isolates were available from 106 
infants. One medical record was missing (serotype V, CC1). 
Thus, 105 infants and their isolates were included in the 
study. There were 60 males (57 %) and 45 (43 %) females. 
There were 56 (53 %) with EOD and 49 (47 %) with LOD. 
Information about the infants, pregnancy and delivery, as 
well as known risk factors for GBS infections, separated into 
EOD and LOD, is shown in Table 1.
Preterm infants were 31 in total (30 %) and out of the 14 
preterm infants with EOD, 8 were born after PROM and 
of these 7 mothers had PROM >24 h before birth. Labour 
was induced in two mothers, one had high fever and the 
other had pre- eclampsia. In total, 55 mothers (52 %) had 1 
or more risk factors for infection, and of those, 36 (65 %) 
were mothers of infants who got EOD. In total, 14 mothers 
received antibiotics intra- partum and of these 6 had infants 
who got EOD and 8 had infants who got LOD (Table 1). 
During the study period six mothers with fever  ≥38 °C 
during delivery did not receive antibiotics; five of those 
cases occurred before 2002.
Epidemiology
The incidence of all invasive GBS infections in infants in 
Iceland from 1975 to 2019 is shown in Fig. 1a. The inci-
dence increased during the first half of the study period 
and peaked in 2000–2004 at 1.15/1000 live births. After 
that, the incidence decreased but increased again at the end 
of the study period in 2015–2019 to 0.67/1000 live births. 
The incidence of EOD increased during the first half of the 
study period and was highest in 1995–1999 at 0.76/1000 
live births and decreased after that and at the end of the 
study period in 2015–2019 the incidence was 0.19/1000 live 
births. The incidence of LOD increased significantly during 
the study period (P=0.0001) and was highest in 2000–2004 
at 0.62/1000 live births. At the end of the study period in 
2015–2019 the incidence was 0.48/1000 live births.
Serotypes and molecular types
The GBS isolates were of six different serotypes, with sero-
type III being the most common. Of 105 isolates, 56 (53 %) 
were serotype III, 23 (22 %) serotype Ia, 9 (9 %) serotype Ib, 
8 (8 %) serotype V, 5 (5 %) serotype II and 3 (3 %) serotype 
IV, while 1 was not typable. The GBS isolates were of seven 
different CCs, with CC17 being the most common. Of 
105 isolates, 39 (38 %) were CC17, 19 (18 %) were CC19, 
18 (17 %) were CC23, 12 (12 %) were CC10, 9 (9 %) were 
CC1, 6 (6 %) were CC7 and 1 (1 %) was CC22. Before the 
turn of the century CC17 comprised <50 % of total isolates. 
The proportion increased significantly over time (P=0.003) 
and CC17 comprised ~80 % of total isolates in 2015–2019 
(Fig. 1b).
Four different types of surface protein genes were found in 
the isolates in the study. In total, 58 (56 %) had the surface 
protein gene RIB (rib), 21 (20 %) the surface protein gene 
BCA (bca), 20 (19 %) the surface protein gene EPS (eps) 
and 5 (5 %) the surface protein gene ALP3 (alp3). The 
GBS isolates had four different combinations of pili. The 
most common combination was PI-1 +PI- 2a among 39 
(38 %) isolates, while 35 (34 %) isolates had PI-1 +PI- 2b, 
21 (20 %) isolates had PI- 2a and 9 (9 %) isolates had PI- 2b. 
GBS CCs were mostly associated with given serotypes, 
surface protein genes and pili as previously reported [30]. 
In total, 18 different lineages of the GBS bacteria were 
found during the study period. The most common lineage 
CC17 of serotype III, with the surface protein gene RIB 
and pili PI-1 +PI- 2b, was found in 30 infections (29 % of 
all isolates).
Table 2. Clinical findings for infants with GBS infections in Iceland from 1975 to 2019 divided by EOD and LOD
Early- onset disease (EOD) Late- onset disease (LOD) All cases P- value
  No. (%) No. (%) No. (%)
No. of cases (%) 56 (53) 49 (47) 105 (100)
Fever ≥38 °C 20 (36) 39 (80) 59 (56) <0.001
Respiratory difficulties 51 (91) 31 (63) 82 (78) 0.001
Hospital stay (days)* 10 [8–14]* 11 [9–26]* 10 [8–17]* 0.18
Sepsis 56 (100) 49 (100) 105 (100) 0.49
Meningitis 6 (11) 12 (24) 18 (17) 0.11
Pneumonia 15 (27) 0 (0) 15 (14) <0.001
*Median (interquartile range).
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Clinical presentation
GBS infections in infants were classified as sepsis alone (the 
most common presentation with 74 infants or 70 %), sepsis 
with meningitis (16 infants or 15 %), sepsis with pneumonia 
(13 infants or 12 %) and sepsis with meningitis and pneu-
monia (2 infants or 2 %). Clinical information on GBS infec-
tions and diagnoses of infants separated by EOD and LOD is 
shown in Table 2. The most common presenting symptoms 
were respiratory difficulties and fever  ≥38 °C. Respiratory 
difficulties were tachypnea (respiratory rate  ≥60/min), 
grunting, retractions and nasal flaring. Respiratory difficul-
ties were significantly more common in EOD than LOD 
(P=0.001), but fever ≥38 °C was significantly more common 
in LOD (P<0.001). Meningitis was more common in LOD 
than EOD, although not significantly, and pneumonia was 
only diagnosed in EOD (Table 2).
There was a significant relationship between CC10 and 
pneumonia (P=0.03), but it was lost after correction for 
multiple testing with the Bonferroni method. There was not 
a significant relationship between CCs and fever or CCs and 
respiratory difficulties (P=0.21 and P=0.20). The relation-
ship between presenting symptoms and serotypes, surface 
proteins and pili was also tested. A significant relationship 
was found between serotypes and fever ≥38 °C (P=0.01), 
where serotype III caused fever more often and serotypes 
II and V less often than expected. There was not a signifi-
cant relationship between presenting symptoms and other 
factors.
A significant relationship was found between CCs and 
infection classification as EOD or LOD (P=0.002) (Fig. 2). 
Moreover, CC17 was significantly more common in LOD 
than EOD (P<0.001). CCs 10, 19 and 23 were more common 
in EOD than LOD, but not significantly (P=0.06, P=0.25, 
P=0.14).
Antibiotics
Of 14 mothers who received intrapartum antibiotic prophy-
laxis, 7 received penicillin (50 %), 4 ampicillin–clavulanic 
acid (29 %), 1 ampicillin, 1 cefazolin and 1 erythromycin with 
gentamicin. Ampicillin with either gentamicin or cefotaxime 
as empirical therapy at presentation was the most common 
antibiotic used for infants with suspected severe infection (96 
infants or 91 %). The most common antibiotic that infants 
received when GBS infection had been confirmed was ampi-
cillin (98 infants or 93 %). Next were gentamicin (62 infants or 
59 %), cefotaxime (40 infants or 38 %), netilmicin (38 infants 
or 36 %) and penicillin (20 infants or 19 %). When informa-
tion on susceptibility was available, ampicillin was usually 
continued alone or changed to penicillin monotherapy.
DISCUSSION
The incidence of invasive GBS infections in infants in Iceland 
decreased from a peak in 2000–2004 until it increased again 
at the end of the study period in 2015–2019. However, when 
considering fluctuations in the incidence in Iceland, the small 
size of the population must be taken into account. In accord-
ance with other studies, the incidence of EOD decreased from 
the turn of the century [1, 31]. This was likely the result of 
preventive measures against EOD, such as intrapartum anti-
biotic prophylaxis for women with known risk factors. In 
agreement with Icelandic studies on GBS infections in infants, 
covering the years 1976–2015, the incidence of LOD increased 
significantly during the study period [16, 26]. More studies 
have shown that the incidence of LOD has remained the same 
or surprisingly increased in recent decades [1, 12, 15, 31–33]. 
At the end of the study period in 2015–2019 the incidence 
of EOD in Iceland was 0.19/1000 live births, slightly lower 
than the incidence of 0.23 recently reported in the USA [34]. 
Interestingly, the incidence of LOD in Iceland was 0.48/1000 
live births at the end of the period, clearly higher than the 
incidence of 0.31 in the USA [34]. It seems that the incidence 
in Iceland is still shifting more towards LOD.
The available isolates were of six different serotypes, with III 
being the most common. This is in context of a recent meta- 
analysis of the epidemiology of neonatal GBS infections that 
included 135 studies showing that serotype III was the most 
common (61.5%) [18]. In our study the GBS isolates were of 
seven different CCs and CC17 was clearly the most common. 
The same has been shown in studies in Sweden and Ireland 
[22, 23], and in the Netherlands CC17 increased in prevalence 
during recent decades [24]. In our study, the hypervirulent 
clone CC17 was also overrepresented and accounted for about 
80 % of all GBS isolates from infants in 2015–2019.
The most common presenting symptoms were respira-
tory difficulties and fever. Respiratory difficulties were 
significantly more common in EOD than LOD, probably 
because pneumonia is more often related to EOD. Fever was 
significantly more common in LOD. This could be because 
the infection is more advanced at the time of diagnosis or 
the infant is more mature at that time. The most common 
Fig. 2. Clonal complexes (CCs) of GBS infections in infants in Iceland 
from 1975 to 2019 divided by early- onset disease (EOD) and late- onset 
disease (LOD).
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presentation in our study was sepsis alone (see Table 2). 
Meningitis was more common in LOD and pneumonia 
was only diagnosed in EOD. Other studies have found 
similar results but with fewer cases of pneumonia in EOD 
[9, 11, 31]. It is conceivable that pneumonia is related to 
EOD because neonates may aspirate colonized amniotic 
fluid or vaginal secretions during the birth process and 
passage through the birth canal. Meningitis could be more 
common in LOD than EOD because of later intervention 
in LOD. Furthermore, infants with LOD had significantly 
lower birthweight than infants with EOD and a higher 
proportion of preterm infants, resulting in lower titres of 
maternal- specific antibodies [35]. Thus, preterm infants 
could be more susceptible to severe LOD infections.
In this study, CC10 was significantly related to pneumonia 
but this relationship was lost after correction for multiple 
testing. To the best of our knowledge, this has not been 
reported before. However, this must be interpreted with 
caution because of the few cases and possible coding differ-
ences for the diagnosis of pneumonia. This study did not 
show a relationship between CC17 and meningitis, as other 
studies have [10, 36]. The proportion of meningitis cases 
among LOD was 24 versus 66 % in a study from France 
[10] and only 6 out of 18 cases of meningitis were caused 
by CC17. It remains uncertain why fewer CC17 meningitis 
cases occurred in Iceland, but one possibility is that infants 
received medical care sooner. However, CC17 was associ-
ated with LOD, as shown in other studies [22, 36]. A study 
from Canada on GBS colonization in pregnant women with 
follow- up after delivery showed that ST17 and ST19 were 
significantly more likely to persist in vaginal samples than 
others, despite antibiotic treatment [37]. The CC17 group 
almost exclusively comprises ST17 [23]. On the same note, 
all three infants with reinfection in our study had CC17. 
It can be postulated that the increase in the use of anti-
biotics during delivery after the turn of the century may 
have had an impact on the increase in the prevalence of 
the hypervirulent clone CC17, as other authors have also 
suggested [38, 39]. The PI-1 and PI- 2b pili that most CC17 
have seem to be important for adherence to epithelial cells 
[40]. Furthermore, the PI- 2b pilus has been shown to play a 
role in invasion and possible spread to the central nervous 
system [41]. In our study there were 39 (37 %) CC17 of 
serotype III with the surface protein gene RIB, 30 had 
pili PI-1 +PI- 2b and 9 only had PI- 2b. Thus, this study is 
consistent with the suggestion that this clone is hyperviru-
lent in neonatal GBS infections.
Risk factors for neonatal GBS infections were confirmed in 
half of the mothers, and two- thirds of their infants got EOD. 
PROM >24 h before birth and fever ≥38 °C during delivery, 
which are known risk factors for EOD [1, 11, 42], were 
more common in EOD than LOD. Risk factors for LOD 
are less clear but maternal carriage of GBS and prematurity 
are two known factors [12]. Preterm infants were 14 (25 %) 
in the EOD group and 17 (35 %) in the LOD group. Twelve 
infants with LOD were infected while still in the hospital, 
suggesting that transmission might have occurred from 
the hospital environment or from their mothers. Those 12 
infants had been admitted for an average of 39 days, 9 were 
born preterm, 1 mother was a known GBS carrier and 3 
mothers received antibiotics intrapartum. Other countries 
have reported hospital transmissions of GBS [43, 44] and 
in our study we found three possible cases of hospital 
transmission.
Fourteen mothers received intrapartum antibiotic prophy-
laxis. Six had children with EOD and four of them had fever 
during delivery, which has been correlated with ineffective-
ness of antibiotics [45]. Eight mothers had infants with LOD 
and five infants were infected with CC17, which has been 
shown to persist in the birth canal [37].
The small number of patients in our study may be regarded 
as a weakness, but we describe GBS infections in infants from 
a whole country over several decades.
A recent meta- analysis of 17 studies comparing screening- 
and risk- based protocols for prevention against neonatal 
GBS infections showed that screening was associated with 
lower incidences of EOD [46]. However, the rising incidence 
of LOD is of concern and other prophylactic measures, such 
as vaccines, are needed [47, 48]. Given the differences in 
serotypes and invasiveness in EOD and LOD it is important 
for every country to follow their epidemiology in the fight 
against neonatal invasive GBS infections.
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